|

A Study of Tirzepatide (LY3298176) in Participants With Type 1 Diabetes Mellitus and Overweight or Obesity

RECRUITINGPhase 1Sponsored by Eli Lilly and Company
Actively Recruiting
PhasePhase 1
SponsorEli Lilly and Company
Started2026-09-11
Est. completion2026-12
Eligibility
Age18 Years – 70 Years
Healthy vol.Accepted
Locations1 site

Summary

The main purpose of this study is to learn more how tirzepatide affects stomach emptying in participants with Type 1 Diabetes Mellitus (T1DM) and overweight or obesity. Participation in this study will last about 8 weeks, including screening and follow-up.

Eligibility

Age: 18 Years – 70 YearsHealthy volunteers accepted
Inclusion Criteria:

* Have a diagnosis of type 1 diabetes mellitus (T1DM) and have been treated with insulin for at least 1 year prior to screening
* Have a body mass index (BMI) greater than or equal to 25.0 kilograms per square meter (kg/m2) at screening
* Are of stable weight, that is a self-reported change of 5 kg or less, for at least 90 days prior to screening

Exclusion Criteria:

* Participants who have a known clinically significant gastric emptying abnormality
* Have undergone weight loss surgery such as gastric bypass (bariatric) surgery or restrictive bariatric surgery
* Have known allergies or intolerance to acetaminophen, tirzepatide, or glucagon-like peptide-1 (GLP-1) receptor agonists

Conditions4

DiabetesDiabetes Mellitus, Type 1ObesityOverweight

Interventions2

Locations1 site

Clinical Pharmacology of Miami
Miami, Florida, 33172
305-817-2900

Find trials near these locations

Related trials

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.